2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
// Nieves González 1,* , Isabel Prieto 2,* , Laura del Puerto-Nevado 3,* , Sergio Portal-Nuñez 4,* , Juan Antonio Ardura 4 , Marta Corton 5 , Beatriz Fernández-Fernández 6,7 , Oscar Aguilera 3 , Carmen Gomez-Guerrero 6 , Sebastián Mas 6 , Juan Antonio Moreno 6 , Marta Ruiz-Ortega 6 , Ana Belen Sanz 6,7 , Maria Dolores Sanchez-Niño 6,7 , Federico Rojo 8 , Fernando Vivanco 9 , Pedro Esbrit 4 , Carmen Ayuso 5 , Gloria Alvarez-Llamas 7,9 , Jesús Egido 1,6 , Jesús García-Foncillas 3 , Alberto Ortiz 6,7 and Diabetes Cancer Connect Consortium 10 1 Renal, Vascular and Diabetes Research Laboratory, IIS-Fundacion Jimenez Diaz-UAM, Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain 2 Radiation Oncology, Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain 3 Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain 4 Bone and Mineral Metabolism laboratory, IIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain 5 Genetics, IIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain 6 Nephrology, IIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain 7 REDINREN, Madrid, Spain 8 Pathology, IIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain 9 Immunology, IIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain 10 Membership of the DiabetesCancerConnect Consortium is provided in the Acknowledgments * These authors have contributed equally to this work Correspondence to: Alberto Ortiz, email: // Keywords : hyperglycemia, inflammation, diabetic kidney disease, colon cancer, diabetes mellitus Received : September 07, 2016 Accepted : December 26, 2016 Published : January 03, 2017 Abstract Worldwide deaths from diabetes mellitus (DM) and colorectal cancer increased by 90% and 57%, respectively, over the past 20 years. The risk of colorectal cancer was estimated to be 27% higher in patients with type 2 DM than in non-diabetic controls. However, there are potential confounders, information from lower income countries is scarce, across the globe there is no correlation between DM prevalence and colorectal cancer incidence and the association has evolved over time, suggesting the impact of additional environmental factors. The clinical relevance of these associations depends on understanding the mechanism involved. Although evidence is limited, insulin use has been associated with increased and metformin with decreased incidence of colorectal cancer. In addition, colorectal cancer shares some cellular and molecular pathways with diabetes target organ damage, exemplified by diabetic kidney disease. These include epithelial cell injury, activation of inflammation and Wnt/β-catenin pathways and iron homeostasis defects, among others. Indeed, some drugs have undergone clinical trials for both cancer and diabetic kidney disease. Genome-wide association studies have identified diabetes-associated genes (e.g. TCF7L2 ) that may also contribute to colorectal cancer. We review the epidemiological evidence, potential pathophysiological mechanisms and therapeutic implications of the association between DM and colorectal cancer. Further studies should clarify the worldwide association between DM and colorectal cancer, strengthen the biological plausibility of a cause-and-effect relationship through characterization of the molecular pathways involved, search for specific molecular signatures of colorectal cancer under diabetic conditions, and eventually explore DM-specific strategies to prevent or treat colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
A metagenome-wide association study of gut microbiota in type 2 diabetes
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et al. (2012) · Nature · doi:10.1038/nature11450 · Cited by 6,762
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435 · cited 1×
“Thus, inflammasome deficiency-related changes in gut microbiota are associated with insulin resistance and obesity [130].”
BackgroundSingh, N., Gurav, A., Sivaprakasam, S., Brady, E., Padia, R., Shi, H., Thangaraju, M., Prasad, P. D., Manicassamy, S., Munn, D. H., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.12.007 · Cited by 2,368 · cited 1×
“Diet, the microbiota and the inflammatory response to the microbiota are potential players [16-22].”
BackgroundGiovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
Grant, S. F. A., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emilsson, V., Helgadottir, A., et al. (2006) · Nature Genetics · doi:10.1038/ng1732 · Cited by 2,287 · cited 1×
“TCF7L2 harbors common genetic variants with the strongest effect on T2DM risk [157-159] and on DM complications such as DKD [160] and is also susceptibility locus for CRC loci in East Asians [161].”
BackgroundMetformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284 · cited 1×
“The preferred initial and most widely used pharmacological agent for T2DM is metformin, which decreases glucose production by inhibiting the mitochondrial glycerophosphate dehydrogenase (GPDH, GPD2) [7].”
BackgroundMolecular and cellular regulation of glucose transporter (GLUT) proteins in cancer
Macheda, M. L., Rogers, S., & Best, J. D. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20166 · Cited by 1,229
Inflammation and cancer: advances and new agents
Crusz, S. M., & Balkwill, F. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.105 · Cited by 1,184
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806 · cited 1×
“The association between DM and CRC may result from shared risk factors between T2DM and cancer but epidemiological data suggest a potential contribution of hyperinsulinemia, hyperglycemia or DM therapy [4, 46, 47] (Figure 2).”
BackgroundVariants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus
Yasuda, K., Miyake, K., Horikawa, Y., Hara, K., Osawa, H., Furuta, H., Hirota, Y., Mori, H., Jonsson, A., Sato, Y., et al. (2008) · Nature Genetics · doi:10.1038/ng.207 · Cited by 776
Targeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis
Odegaard, J. I., & Chawla, A. (2013) · Science · doi:10.1126/science.1230721 · Cited by 643 · cited 1×
“Inflammation is a critical component of diabetesinduced target organ injury and of CRC initiation and progression [112, 113].”
BackgroundBennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609 · cited 1×
“If adequate glucose control is not achieved within 3-6 months, a second oral agent, a Glucagon-like peptide-1 (GLP-1) receptor agonist, or insulin should be added [8, 9].”
BackgroundLiang, J., Nagahashi, M., Kim, E. Y., Harikumar, K. B., Yamada, A., Huang, W.-C., Hait, N. C., Allegood, J. C., Price, M. M., Avni, D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.013 · Cited by 563
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44774 · Cited by 547 · cited 3×
“mTOR inhibitors Several agents Yes Yes Yes No (Yes in non-DKD CKD) [98-99, 269]”
BackgroundmTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44771 · Cited by 538
(2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.08.014 · Cited by 536
Dayeh, T., Volkov, P., Salö, S., Hall, E., Nilsson, E., Olsson, A. H., Kirkpatrick, C. L., Wollheim, C. B., Eliasson, L., Rönn, T., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004160 · Cited by 523 · cited 1×
“In this regard, SEPT9 is differentially methylated in human T2DM islet cells and was shown to perturb insulin and glucagon secretion [145].”
Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells
Belcheva, A., Irrazabal, T., Robertson, S. J., Streutker, C., Maughan, H., Rubino, S., Moriyama, E. H., Copeland, J. K., Surendra, A., Kumar, S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.04.051 · Cited by 473
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071583 · Cited by 428 · cited 3×
“Metformin use has been associated with a decreased risk of colon cancer and increased survival [210, 218, 219].”
BackgroundThiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Govindarajan, R., Ratnasinghe, L., Simmons, D. L., Siegel, E. R., Midathada, M. V., Kim, L., Kim, P. J., Owens, R. J., & Lang, N. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2777 · Cited by 336 · cited 1×
“A systematic review and meta-analysis of 840, 787 diabetic patients did not support an association between thiazolidinediones and CRC [229, 230].”
BackgroundInflammation: A driving force speeds cancer metastasis
Wu, Y., & Zhou, B. P. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9699 · Cited by 327
Lee, A., & Morley, J. E. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00314.x · Cited by 320 · cited 1×
“It reduces circulating insulin, promotes weight loss and activates 5’ adenosine monophosphateactivated protein kinase (AMPK), thus inhibiting growth of colon cancer cells [221, 222].”
BackgroundA trial of calcium and vitamin D for the prevention of colorectal adenomas
Baron, J. A., Barry, E. L., Mott, L. A., Rees, J. R., Sandler, R. S., Snover, D. C., Bostick, R. M., Ivanova, A., Cole, B. F., Ahnen, D. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500409 · Cited by 315
Baxter, N. T., Zackular, J. P., Chen, G. Y., & Schloss, P. D. (2014) · Microbiome · doi:10.1186/2049-2618-2-20 · Cited by 299 · cited 1×
“In mice, the microbiota potential for butyrate production negatively correlated with tumor count [133].”
BackgroundMicrobial modulation of insulin sensitivity
Khan, M. T., Nieuwdorp, M., & Bäckhed, F. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.006 · Cited by 260
Metformin suppresses intestinal polyp growth in Apc Min/+ mice
Tomimoto, A., Endo, H., Sugiyama, M., Fujisawa, T., Hosono, K., Takahashi, H., Nakajima, N., Nagashima, Y., Wada, K., Nakagama, H., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00933.x · Cited by 185 · cited 1×
“In mice with Apc mutations, metformin suppressed polyp growth [223] and in diabetic mice metformin, alone or in combination with oxaliplatin, reduced the severity of colorectal tumors [224].”
BackgroundCai, W., He, J. C., Zhu, L., Lu, C., & Vlassara, H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600362103 · Cited by 163 · cited 1×
“High-glucose, AGE, angiotensin II, and proinflammatory cytokines, such as TWEAK and parathyroid hormone-related protein (PTHrP) AGE promote EGFR transactivation in kidney cells [92-96]In this regard, TWEAK targeting antibodies are undergoing clinical trials in kidney disease, while targeting the TWEAK receptor Fn14 re…”
BackgroundBloomfield, H. E., Koeller, E., Greer, N., MacDonald, R., Kane, R., & Wilt, T. J. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0361 · Cited by 159
3. Foundations of Care and Comprehensive Medical Evaluation
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s006 · Cited by 159
Wu, L., Zhu, J., Prokop, L. J., & Murad, M. H. (2015) · Scientific Reports · doi:10.1038/srep10147 · Cited by 144 · cited 1×
“com/oncotarget observational studies and randomized controlled trials (RCTs), respectively, suggested that metformin or thiazolidinediones were associated with a lower risk of all cancer incidence, while insulin, sulfonylureas and alpha glucosidase inhibitors were associated with an increased risk of cancer incidence…”
BackgroundColon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis
Rokkas, T., & Portincasa, P. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.05.027 · Cited by 34
Cited by
Chang, V. C., Cotterchio, M., De, P., & Tinmouth, J. (2021) · Cancer Causes & Control · doi:10.1007/s10552-021-01456-8 · Cited by 74
Metadata
- Authors
- González, N., Diabetes Cancer Connect Consortium, Prieto, I., del Puerto-Nevado, L., Portal-Nuñez, S., Ardura, J. A., Corton, M., Fernández-Fernández, B., Aguilera, O., Gomez-Guerrero, C., Mas, S., Moreno, J. A., Ruiz-Ortega, M., Sanz, A. B., Sanchez-Niño, M. D., Rojo, F., Vivanco, F., Esbrit, P., Ayuso, C., Alvarez-Llamas, G., Egido, J., García-Foncillas, J., & Ortiz, A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-01-03
- Volume
- 8
- Issue
- 11
- Pages
- 18456-18485
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2568726620
- Cited by
- 168
- References
- 43
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.